

**TITLE: The Andrographolide analogue 3A.1 synergizes with Taxane derivatives in aggressive metastatic prostate cancers by upregulation of Heat Shock proteins and downregulation of MAT2A-mediated cell migration and invasion**

Taraswi Mitra Ghosh<sup>1</sup>, Teeratas Kansom<sup>1,2</sup>, Suman Mazumder<sup>1,4</sup>, Joshua Davis<sup>1</sup>, Ahmed S. Alnaim<sup>1</sup>, Shanese L. Jasper<sup>1</sup>, Chu Zhang<sup>1</sup>, Aedan Bird<sup>1</sup>, Praneet Opanasopit<sup>2</sup>, Amit K Mitra<sup>1,3,4</sup> and Robert D. Arnold<sup>1,3,\*</sup>

<sup>1</sup>Department of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.

<sup>2</sup>Department of Pharmaceutical Technology, Faculty of Pharmacy, Silpakorn University, Thailand.

<sup>3</sup>University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.

<sup>4</sup>Center for Pharmacogenomics and Single-Cell Omics Initiative, Auburn University, Auburn, AL, USA

**\*Corresponding Author:**

**Robert D. Arnold, Ph.D.**

Professor, Department of Drug Discovery & Development,  
Auburn University, Harrison School of Pharmacy  
Pharmaceutical Research Building  
720 South Donahue Drive, Rm. 257  
Auburn, AL 36849  
Phone: (334) 844-8434  
Email: rda0007@auburn.edu

<b>Gene symbol</b>	<b>Fold change (3A.1 vs. No treatment)</b>	<b>Fold change (CBZ + 3A.1 vs. No treatment)</b>	<b>Fold change (DTX + 3A.1 vs. No treatment)</b>
<b>ACSM3</b>	-13.28	NA	NA
<b>AKR1C3</b>	-10.57	-14.14	-12.31
<b>ALDH3B1</b>	-11.87	-12.84	-17.22
<b>ALOXE3</b>	22.28	NA	19.51
<b>ANKRD1</b>	21.76	23.82	22.25
<b>ARC</b>	NA	45.56	40.52
<b>ASIC1</b>	NA	NA	-11.88
<b>ATG16L2</b>	NA	-15.82	NA
<b>ATP8A1</b>	-22.30	-23.81	-25.30
<b>CELSR2</b>	-11.43	-13.73	-13.68
<b>CRYAB</b>	206.28	195.57	181.22
<b>CSRP2</b>	20.03	20.81	20.05
<b>CYP4F11</b>	-26.26	-19.74	NA
<b>DNAJB1</b>	25.01	30.04	26.57
<b>DUSP5</b>	23.39	24.18	23.71
<b>EGR1</b>	-11.16	NA	NA
<b>ELF3</b>	-10.95	-27.91	-10.68
<b>EPOR</b>	NA	NA	-9.59
<b>F2RL2</b>	-12.24	-18.26	-16.00
<b>FBN1</b>	-11.79	-12.83	-11.81
<b>GEM</b>	NA	19.94	NA
<b>GXYLT2</b>	-10.16	-13.11	-14.73
<b>HMOX1</b>	59.20	55.14	58.94
<b>HSPA6</b>	2510.81	2733.81	2444.27
<b>HSPB1</b>	24.32	21.29	20.87
<b>HSPH1</b>	24.13	26.41	23.21
<b>IGFBP5</b>	-25.14	-68.63	-32.05
<b>KBTBD8</b>	NA	20.61	NA
<b>LCP1</b>	53.02	46.95	53.85
<b>MAFF</b>	NA	20.82	20.14
<b>MARCHF4</b>	35.17	32.31	34.05
<b>MROH6</b>	NA	-12.44	NA
<b>NDNF</b>	-11.30	NA	-13.63
<b>NPNT</b>	-41.23	-29.80	-29.38
<b>NPR1</b>	NA	NA	-9.69
<b>PDGFD</b>	-14.55	NA	-10.08
<b>PGF</b>	38.22	38.85	36.37
<b>PKIB</b>	28.40	28.56	25.66
<b>PLEKHO1</b>	19.93	NA	NA

<b>PLIN2</b>	22.47	NA	20.56
<b>PTGES</b>	-9.90	-14.82	-10.26
<b>RAB3D</b>	NA	NA	-9.74
<b>RAP1GAP</b>	-15.12	-13.67	-15.75
<b>RNF207</b>	NA	-15.20	NA
<b>RNF43</b>	NA	NA	-11.27
<b>RPLP0P2</b>	91.84	85.45	87.96
<b>S1PR5</b>	-10.96	-19.18	-12.31
<b>SELENOP</b>	-11.91	-15.04	NA
<b>SEMA4G</b>	NA	-24.57	-13.14
<b>SERPIND1</b>	27.27	21.94	29.57
<b>SESN2</b>	26.87	27.25	26.34
<b>SHANK1</b>	19.97	NA	NA
<b>SLC4A8</b>	NA	-15.04	NA
<b>SPHK1</b>	43.10	45.45	42.68
<b>SPNS2</b>	37.85	31.86	32.60
<b>SPOCD1</b>	25.10	NA	21.27
<b>SPRY4</b>	25.74	28.46	24.86
<b>SPTB</b>	NA	26.43	NA
<b>TAS1R3</b>	-18.08	-18.70	-17.34
<b>TGFB3</b>	-26.50	-33.39	-22.37
<b>TMEM8B</b>	-10.10	NA	NA
<b>TNS2</b>	NA	-13.55	NA
<b>TXNIP</b>	-13.19	-18.11	-13.59
<b>VWA7</b>	-9.74	NA	NA
<b>XXYL1</b>	-10.63	NA	NA
<b>ZFAND2A</b>	29.48	33.81	28.18
<b>ZNF467</b>	NA	-14.99	-12.55

Supplementary Table 1 Top differentially expressed genes (DEGs) in Taxane resistant mCRPC cell line (DUTXR). Fold change compared to the untreated group for each cell line. Following 48 h of 3A.1, 3A.1+DTX, and 3A.1+CBZ treatment in DUTXR (taxane resistant AI-mCRPC/NEPC) cell lines. Fold change cut-off value is >1.5.